Brilacidin for OM was given fast track designation by FDA in 2015. Partnering with a medium to large sized Pharma that has capacity for quick P-3 recruiting, plus the relatively easy "swish and spit" advantage, might shorten your proposed timelines.
Especially if Leo has already been in discussions with potential partners, something that has been generally stated in previous Qs.
As more B research results have rolled in expanding B's virucidal scope,
why would Leo pivot back to B for OM and get a payer analysis done if there is no interest?
News 
Market Data 
Discover 
